LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

BACKGROUND: Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI). METHODS: We conducted a multicenter, retrospective pan-cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Landon C, Tucker, Matthew D, Sedhom, Ramy, Schwartz, Eric B, Zhu, Jason, Kao, Chester, Labriola, Matthew K, Gupta, Rajan T, Marin, Daniele, Wu, Yuan, Gupta, Santosh, Zhang, Tian, Harrison, Michael R, George, Daniel J, Alva, Ajjai, Antonarakis, Emmanuel S, Armstrong, Andrew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929846/
https://www.ncbi.nlm.nih.gov/pubmed/33653800
http://dx.doi.org/10.1136/jitc-2020-001792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929846/
https://www.ncbi.nlm.nih.gov/pubmed/33653800
http://dx.doi.org/10.1136/jitc-2020-001792

Ejemplares similares